Minerva Surgical (UTRS) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	UTRS
Title of 12(b) Security	Common Stock, $ 0.001 par value
Security Exchange Name	NASDAQ
Entity Registrant Name	MINERVA SURGICAL, INC.
Entity Central Index Key	0001452965
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		28,968,530
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40919
Entity Tax Identification Number	26-3422906
Entity Address, Address Line One	4255 Burton Dr.
Entity Address, City or Town	Santa Clara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	855
Local Phone Number	646-7874
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,112	$ 40,608
Restricted cash, current	8,024	7,283
Accounts receivable, net	6,791	7,292
Inventory	17,003	15,682
Prepaid expenses and other current assets	2,265	4,139
Total current assets	49,195	75,004
Restricted cash, net of current portion	265	524
Intangible asset, net	28,884	34,970
Property and equipment, net	5,031	4,594
Operating lease right-of-use asset	429
Total assets	83,804	115,092
Current Liabilities:
Accounts payable	2,822	3,629
Accrued compensation	4,224	3,518
Accrued liabilities	10,384	10,662
Contingent consideration liability, current	5,000	5,000
Operating lease liability	565
Total current liabilities	22,995	22,809
Long-term debt	39,271	39,085
Contingent consideration liability, net of current portion		9,094
Total liabilities	62,266	70,988
Commitments and contingencies (Note 8)
Stockholders’ deficit:
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued and outstanding as of September 30, 2022 and December 31, 2021
Common stock, $0.001 par value, 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 28,968,185 shares and 28,822,283 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	28	28
Additional paid-in capital	298,922	293,621
Accumulated other comprehensive income	11	11
Accumulated deficit	(277,423)	(249,556)
Total stockholders' equity	21,538	44,104
Total liabilities and stockholders equity	$ 83,804	$ 115,092

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares, Issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, Issued	28,968,185	28,822,283
Common stock, shares, outstanding	28,968,185	28,822,283

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 12,588	$ 12,506	$ 36,490	$ 38,458
Cost of goods sold	5,775	5,373	16,619	15,760
Gross profit	6,813	7,133	19,871	22,698
Operating expenses
Sales and marketing	9,723	7,919	28,887	22,883
General and administrative	6,142	3,987	12,706	18,115
Research and development	1,456	1,367	3,985	4,191
Total operating expenses	17,321	13,273	45,578	45,189
Loss from operations	(10,508)	(6,140)	(25,707)	(22,491)
Interest income	42		70
Interest expense (includes $nil million and $1.3 million to related parties in three months ended September 30, 2022 and 2021, respectively and $nil million and $4.2 million to related parties in nine months ended September 30, 2022 and 2021, respectively)	(861)	(3,611)	(2,196)	(10,663)
Change in fair value of derivative liabilities		23,383		15,243
Loss on extinguishment of convertible notes		(16,853)		(16,853)
Gain on extinguishment of PPP loan				3,036
Other income (expense), net	(2)	(4)	(34)	(544)
Net loss before income taxes	(11,329)	(3,225)	(27,867)	(32,272)
Income tax benefit (expense)	0	0	0	0
Net Loss	$ (11,329)	$ (3,225)	$ (27,867)	$ (32,272)
Net loss per share attributable to common stockholders, basic	$ (0.40)	$ (1.15)	$ (0.98)	$ (15.04)
Net loss per share attributable to common stockholders, diluted	$ (0.40)	$ (1.15)	$ (0.98)	$ (15.04)
Weighted-average shares used in computing net loss per share, basic and diluted	28,611,045	2,798,146	28,553,949	2,145,733

Condensed Statements of Opera_2

Condensed Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Interest Expense, Related Party	$ 0	$ 1,300	$ 0	$ 4,200

Condensed Statements of Redeema

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2020	$ (221,811)		$ 1	$ 6,269	$ 11	$ (228,092)
Temporary Equity, Balance, shares at Dec. 31, 2020		12,397,838
Temporary Equity, Balance at Dec. 31, 2020		$ 123,255
Balance, shares at Dec. 31, 2020			1,192,299
Issuance of common stock upon exercise of stock options	886		$ 2	884
Issuance of common stock upon exercise of stock options, shares			1,465,158
Issuance of common stock upon early exercise of stock options, shares			363,555
Stock-based compensation expense	131			131
Net loss	(14,948)					(14,948)
Balance at Mar. 31, 2021	(235,742)		$ 3	7,284	11	(243,040)
Temporary Equity, Balance, shares at Mar. 31, 2021		12,397,838
Temporary Equity, Balance at Mar. 31, 2021		$ 123,255
Balance, shares at Mar. 31, 2021			3,021,012
Balance at Dec. 31, 2020	(221,811)		$ 1	6,269	11	(228,092)
Temporary Equity, Balance, shares at Dec. 31, 2020		12,397,838
Temporary Equity, Balance at Dec. 31, 2020		$ 123,255
Balance, shares at Dec. 31, 2020			1,192,299
Net loss	(32,272)
Balance at Sep. 30, 2021	(247,382)		$ 3	12,968	11	(260,364)
Temporary Equity, Balance, shares at Sep. 30, 2021		12,397,838
Temporary Equity, Balance at Sep. 30, 2021		$ 123,255
Balance, shares at Sep. 30, 2021			3,149,777
Balance at Mar. 31, 2021	(235,742)		$ 3	7,284	11	(243,040)
Temporary Equity, Balance, shares at Mar. 31, 2021		12,397,838
Temporary Equity, Balance at Mar. 31, 2021		$ 123,255
Balance, shares at Mar. 31, 2021			3,021,012
Issuance of common stock upon exercise of stock options	40			40
Issuance of common stock upon exercise of stock options, shares			66,288
Vesting of early exercised stock options	15			15
Stock-based compensation expense	4,478			4,478
Net loss	(14,099)					(14,099)
Balance at Jun. 30, 2021	(245,308)		$ 3	11,817	11	(257,139)
Temporary Equity, Balance, shares at Jun. 30, 2021		12,397,838
Temporary Equity, Balance at Jun. 30, 2021		$ 123,255
Balance, shares at Jun. 30, 2021			3,087,300
Issuance of common stock upon exercise of stock options	37			37
Issuance of common stock upon exercise of stock options, shares			62,477
Vesting of early exercised stock options	39			39
Stock-based compensation expense	1,075			1,075
Net loss	(3,225)					(3,225)
Balance at Sep. 30, 2021	(247,382)		$ 3	12,968	11	(260,364)
Temporary Equity, Balance, shares at Sep. 30, 2021		12,397,838
Temporary Equity, Balance at Sep. 30, 2021		$ 123,255
Balance, shares at Sep. 30, 2021			3,149,777
Balance at Dec. 31, 2021	44,104		$ 28	293,621	11	(249,556)
Balance, shares at Dec. 31, 2021			28,822,283
Issuance of common stock upon exercise of stock options	3			3
Issuance of common stock upon exercise of stock options, shares			5,166
Vesting of early exercised stock options	39			39
Stock-based compensation expense	1,523			1,523
Net loss	(10,925)					(10,925)
Balance at Mar. 31, 2022	34,744		$ 28	295,186	11	(260,481)
Balance, shares at Mar. 31, 2022			28,827,449
Balance at Dec. 31, 2021	$ 44,104		$ 28	293,621	11	(249,556)
Balance, shares at Dec. 31, 2021			28,822,283
Issuance of common stock upon exercise of stock options, shares	56,964
Net loss	$ (27,867)
Balance at Sep. 30, 2022	21,538		$ 28	298,922	11	(277,423)
Balance, shares at Sep. 30, 2022			28,968,185
Balance at Mar. 31, 2022	34,744		$ 28	295,186	11	(260,481)
Balance, shares at Mar. 31, 2022			28,827,449
Issuance of common stock upon exercise of stock options	18			18
Issuance of common stock upon exercise of stock options, shares			28,875
Vesting of early exercised stock options	25			25
Stock-based compensation expense	1,676			1,676
Net loss	(5,613)					(5,613)
Balance at Jun. 30, 2022	30,850		$ 28	296,905	11	(266,094)
Balance, shares at Jun. 30, 2022			28,856,324
Issuance of common stock upon release of RSUs			88,938
Issuance of common stock upon exercise of stock options	13			13
Issuance of common stock upon exercise of stock options, shares			22,923
Vesting of early exercised stock options	27			27
Stock-based compensation expense	1,977			1,977
Net loss	(11,329)					(11,329)
Balance at Sep. 30, 2022	$ 21,538		$ 28	$ 298,922	$ 11	$ (277,423)
Balance, shares at Sep. 30, 2022			28,968,185

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Cash Flows From Operating Activities:
Net loss	$ (27,867)	$ (32,272)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and debt issuance costs	186	3,342
Non-cash interest expense from long-term debt and convertible notes		5,395
Loss on extinguishment of convertible notes		16,853
Depreciation and amortization	8,053	7,948
Non-cash lease expense	465
Gain on extinguishment of PPP loan		(3,036)
Stock-based compensation expense	5,176	5,684
Change in fair value of redeemable convertible preferred stock warrant liability		535
Change in fair value of contingent consideration liability	(4,094)	780
Change in fair value of derivative liabilities		(15,243)
Property and equipment write-downs/disposals	10
Net changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable, net	501	1,621
Inventory	(3,610)	(6,600)
Prepaid expenses and other current assets	1,874	(2,461)
Accounts payable	(807)	4,951
Accrued liabilities	90	1,227
Accrued compensation	706	(30)
Operating lease liability	(606)
Net cash used in operating activities	(19,923)	(11,306)
Cash Flows From Investing Activities:
Purchase of property and equipment	(125)	(888)
Net cash used in investing activities	(125)	(888)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock	34	963
Payment of contingent consideration	(5,000)
Net cash (used in) provided by financing activities	(4,966)	963
Net decrease in cash, cash equivalents and restricted cash	(25,014)	(11,231)
Cash, cash equivalents and restricted cash at the beginning of the period	48,415	25,166
Cash, cash equivalents and restricted cash at the end of the period	23,401	13,935
Reconciliation of cash, cash equivalents and restricted cash to balance sheets
Cash and cash equivalents	15,112	6,128
Restricted cash	8,289	7,807
Cash, cash equivalents and restricted cash in balance sheets	23,401	13,935
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	1,930	1,894
Supplemental Disclosure of Non-cash Items:
Forgiveness of PPA Loan		(3,036)
Vesting of early exercised stock options	91	54
Net reclassification of inventory to property and equipment for customer usage agreements	2,289	$ 1,934
Right of use asset acquired under operating lease on the adoption of ASC 842	$ 894

Formation and Business of the C

Formation and Business of the Company	9 Months Ended
	Sep. 30, 2022
Disclosure Text Block [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company The Company Minerva Surgical, Inc. (the Company, we, us, and our) was incorporated in the state of Delaware on November 3, 2008. The Company's headquarters are in Santa Clara, California. The Company is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company commenced commercial introduction of its products in the United States in 2015 following the clearance by the U.S. Food and Drug Administration (FDA). In May 2020, the Company acquired certain assets from Boston Scientific Corporation (BSC) to broaden its product offerings to its customers. The Company derives all of its revenue from sales to customers in the United States through a direct sales force. Initial Public Offering On October 21, 2021, the Company's registration statement on Form S-1 (File No. 333- 259832) relating to its initial public offering (IPO) of common stock became effective. T he Company issued and sold 6,250,000 shares of its common stock at a public offering price of $ 12.00 per share, for aggregate gross proceeds of $ 75.0 million. The Company received $ 69.8 million in net proceeds after deducting underwriting discounts and commissions. The total IPO offering costs other than underwriting discounts and commissions were $ 3.2 million. In connection with the completion of its IPO, on October 21, 2021, the Company's certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 5,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share. Immediately prior to the IPO, $ 79.2 million in aggregate outstanding principal and accrued interest of the convertible promissory notes converted into 7,006,228 shares of redeemable convertible preferred stock at a conversion price of $ 11.31 per share. Also, immediately prior to the closing, all outstanding shares of the Company's redeemable convertible preferred stock (including those issued upon conversion of the convertible promissory notes) converted into 19,404,066 shares of common stock which resulted in the reclassification of the carrying value of the preferred stock to common stock and additional paid-in capital. Liquidity In accordance with ASC 205-40, Presentation of Financial Statements – Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the financial statements are issued. The Company’s financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company incurred a net loss of $ 27.9 million during the nine months ended September 30, 2022 and had an accumulated deficit of $ 277.4 million as of September 30, 2022. T he Company had cash and cash equivalents of $ 15.1 million as of September 30, 2022. The Company has prepared an internal forecast that was reviewed with our Board of Directors that includes plans to raise additional capital within the next three to six months. Should the plan to raise capital within this timeline not be consummated, this forecast presents the possibility that Company’s cash and cash equivalents are not sufficient to fund its operations within the next twelve-months. As of September 30, 2022, the Company was in compliance with the financial covenants required by its Loan and Security Agreement with Canadian Imperial Bank of Commerce (the CIBC Agreement). However, the inherent uncertainties described above may impact the Company’s ability to remain in compliance with these covenants over the next twelve months. A potential financial covenant violation, should it occur, would put the company in technical default per the terms of the CIBC Agreement and provide for remedies to the bank per that agreement. These circumstances impact the Company's ability to fund its current business plan within the twelve months from the date of issuance of these financial statements. The presence of these conditions, individually or in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is currently in discussions with a number of potential lenders and investors to raise additional capital through debt, equity or a combination financing. Such additional financing may or may not be available to the Company on acceptable terms, or at all. If the Company is unable obtain adequate financing on acceptable terms, the Company may terminate or delay the development of one or more of its products, delay sales and marketing efforts or other activities necessary to commercialize its products, or modify its operations to operate within available resources. Failure to manage discretionary spending or raise additional financing as needed, may adversely impact the Company’s ability to achieve its intended business objectives. While the Company believes its plans will alleviate the conditions that raise substantial doubt about its ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring. Impact of the COVID-19 pandemic The COVID-19 pandemic and the resulting economic downturn have impacted business conditions in the industry in which the Company operates. Since March 2020, the Company’s net sales were negatively impacted by the COVID-19 pandemic as hospitals and ambulatory surgical centers (ASCs) delayed or canceled elective procedures. In response to the pandemic, many state and local governments in the U.S. issued orders that temporarily precluded elective procedures in order to conserve scarce health system resources. The decrease in hospital and ASCs admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's products. The Company continued to experience a slower than expected revenue growth in the nine months ended September 30, 2022, a trend that continued from the second half of 2021. While reinstated hospital and ASC closures for elective procedures due to COVID-19 have been lifted in most hospitals and ASCs in the nine months ended September 30, 2022, a nationwide staffing shortage in the hospital work environment resulted in a negative impact on the numbers of ablation procedures scheduled during that time. The Company has taken necessary precautions to safeguard its employees, patients, customers, and other stakeholders from the COVID-19 pandemic, while maintaining business continuity to support its patients, customers and employees. The timing, extent and continuation of any increase in procedures, and any corresponding increase in sales of the Company’s products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors. The Company is continuing to monitor the impact of the COVID-19 pandemic on its employees and customers and on the markets in which it operates and will take further actions that the Company considers prudent to address the COVID-19 pandemic, while ensuring that it can support its customers and continue to develop its products. The ultimate extent of the impact of the COVID-19 pandemic on the Company is highly uncertain and subject to change. This impact may result in a material, adverse impact on liquidity, capital resources, supply chain, operations and revenue and may affect third parties in which the Company relies and could worsen over time. The extent of the continuing resurgence of COVID-19, the efficacy and extent of distribution of vaccines, and the impact of variants of COVID-19 is unpredictable.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP). Certain prior year amounts have been reclassified to conform to the current year presentation. Reverse Stock Split On October 14, 2021, the Company effected a 1 -for-6.046 reverse stock split of its outstanding common stock and redeemable convertible preferred stock. Upon the effectiveness of the reverse stock split, all issued and outstanding shares of common stock, options to purchase common stock, warrants, instruments convertible to shares, redeemable convertible preferred stock and related share data and per share amounts contained in the accompanying financial statements were retroactively revised to reflect this reverse stock split for all periods presented. The par value of the authorized stock was not adjusted as a result of the reverse stock split. Unaudited interim financial information The accompanying condensed balance sheet as of September 30, 2022, the condensed statements of operations, the condensed statements of redeemable convertible preferred stock and stockholders’ equity and condensed statements of cash flows for the periods ended September 30, 2022 and 2021 are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the 2021 audited annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2022 and the results of its operations and its cash flows for the three- and nine-month periods ended September 30, 2022 and 2021. The financial data and other information disclosed in these notes related to the three- and nine-month periods ended September 30, 2022 and 2021 are also unaudited. The results for the three- and nine-month periods ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. The balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the interim condensed financial statements. These unaudited interim condensed financial statements should be read in conjunction with the audited annual financial statements and related notes. The significant accounting policies used in the preparation of the unaudited condensed financial statements for the three- and nine-month periods ended September 30, 2022 and 2021, are consistent with those discussed in Note 2 to the audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 23, 2022. There have been no significant changes in the significant accounting policies or critical accounting estimates since December 31, 2021, except for the accounting policy related to ASU 2016-02, Leases discussed below. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, including definite-lived intangible assets, revaluation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, contingent consideration liability, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, deferred tax assets and related valuation allowances, impact of contingencies and the Company’s incremental borrowing rate used to calculate lease assets . Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates its fair value and is classified as a Level 2 liability. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At September 30, 2022 and 2021, and for the periods then ended, no customer accounted for more than 10.0% of accounts receivable or revenue. Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect our results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event. Lease Prior to January 1, 2022, the Company met the requirements to account for leases of its facilities as operating leases under ASC 840. The Company recognized rent expense on a straight-line basis over the non-cancellable lease term. Where leases contain escalation clauses, rent abatements or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applied them in the determination of straight-line rent expense over the lease term. The Company recorded the difference between the rent paid and the straight-line rent as a deferred rent liability. Upon adoption of ASU 2016-02, Leases (Topic 842) , and the related amendments (ASC 842), on January 1, 2022, the Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the Company's balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. For a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company’s statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of twelve months or less. Variable lease payments are expensed as incurred. Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. Net loss per share attributable to common stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders, by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was considered a participating security because it participated in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock did not have a contractual obligation to share in the Company’s losses for the three- and nine-month periods ended September 30, 2021. Prior to the three- and nine-month periods ended September 30, 2022 all the redeemable convertible preferred stock were converted into shares of common stock. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for the three- and nine-month periods ended September 30, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for all periods presented.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements The Company adopted ASC 842 effective Ja nuary 1, 2022 , using the modified retrospective approach with a cumulative effect adjustment to the accumulated deficit at the beginning of the period of adoption. The Company elected the transition practical expedient package, including (1) to not reassess whether any expired or existing contract are or contain leases; (2) to maintain existing lease classifications for expired or existing leases; and (3) to not reassess whether previously capitalized initial direct costs qualify for capitalization under Topic ASC 842. Upon adoption of ASC 842, the Company recognized a right of use (ROU) asset of $ 0.9 million and an operating lease liability of $ 1.2 million and derecognized deferred rent of $ 0.3 million related to the operating leases on the balance sheets as of January 1, 2022 with no impact to the condensed statements of operations, condensed statements of redeemable convertible preferred stock and stockholder’s equity or condensed statements of cash flows. The additional disclosures required by the new standard have been included in Note 8, Commitments and Contingencies.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	4. Revenue Disaggregation of revenue Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Minerva ES 46.8 % 46.1 % 45.1 % 46.8 % Genesys HTA 28.4 % 31.2 % 29.5 % 32.0 % Symphion 24.1 % 22.0 % 24.8 % 20.2 % Other 0.7 % 0.7 % 0.6 % 1.0 % 100 % 100 % 100 % 100 % For the three months ended September 30, 2022 and 2021, approximately 99.9 % and 99.0 % of the Company’s revenue is subject to point-in-time recognition for single-use (disposable) products and capital equipment across all revenue streams. Sale of extended warranties on capital equipment within other revenue represents less than 0.1 % and 1.0 % of the Company’s revenue for the three-m onth periods ended on September 30, 2022 and 2021. In addition, for the three months ended September 30, 2022 and 2021, 97.0 % a nd 98.1 % of the Company’s total revenue is derived from the sale of single-use (disposable) products; therefore, the Company did not include disaggregated revenue data to present the amounts attributed to capital equipment, associated warranties, and miscellaneous revenue separately. For the nine months ended September 30, 2022 and 2021 , approximately 99.9 % and 99.0 % of the Company’s revenue is subject to point-in-time recognition for single-use (disposable) products and capital equipment across all revenue streams. Sale of extended warranties on capital equipment within other revenue represents less than 0.1 % and 1.0 % of the Company’s revenue for the nine-month periods ended on September 30, 2022 and 2021, respectively. In addition, for the nine months ended September 30, 2022 and 2021, 98.0 % and 96.8 % of the Company’s total revenue is derived from the sale of single-use (disposable) products; therefore, the Company did not include disaggregated revenue data to present the amounts attributed to capital equipment, associated warranties, and miscellaneous revenue separately. Contract balances The Company’s contract balances consist of the following (in thousands): September 30, December 31, 2022 2021 Accounts receivable, net $ 6,791 $ 7,292 Contract liability—current (see "Note 6") $ 362 $ 206

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair value measurements	5. Fair value measurements ASC 820, Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis —Financial assets held by the Company measured at fair value on a recurring basis include money market funds which are classified as Level 1 within the fair value hierarchy as the inputs used to measure fair value are quoted prices in active markets for identical assets. Contingent consideration liability is remeasured at fair value as of each reporting period and is considered a Level 3 measurement. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Fair value of assets and liabilities The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 13,042 $ — $ — $ 13,042 Total financial assets $ 13,042 $ — $ — $ 13,042 Liability: Contingent consideration liability $ — $ — $ 5,000 $ 5,000 Total financial liabilities $ — $ — $ 5,000 $ 5,000 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 38,522 $ — $ — $ 38,522 Total financial assets $ 38,522 $ — $ — $ 38,522 Liability: Contingent consideration liability $ — $ — $ 14,094 $ 14,094 Total financial liabilities $ — $ — $ 14,094 $ 14,094 Contingent consideration related to the BSC development and revenue milestones is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios, and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in general and administrative expense, in the statements of operations. Prior to the Company’s IPO in October 2021, the Company also had the following financial instruments based on Level 3 FV measurements: The redeemable convertible preferred stock warrant liability is classified within Level 3 of the fair value hierarchy because it is valued using the Black-Scholes pricing model, which requires subjective unobservable inputs. The fair value of the mandatory prepayment derivative liability, as a result of a change in control, was calculated using the “with and without” methodology at loan issuance. The “with and without” methodology involves valuing the term loan on an as-is basis and then valuing the term loan without the embedded derivatives. The difference between the value of the term loan with the embedded derivatives and the value without each individual embedded derivative equals the fair value of the embedded derivative. On the subsequent dates, the Company used an income approach to value the term loan derivative liabilities, where the proceeds to the lenders were estimated, adjusted by the opportunity cost of the lenders for foregoing the debt portion of the instrument. Upon repayment of the Ares Loan in October 2021, the mandatory prepayment derivative liability had no value, because the Company assessed the probability of change in control event to be zero after the IPO. The Company valued the convertible notes derivative liabilities using the income approach, where the proceeds to the convertible noteholders were estimated under different future scenarios, adjusted by the opportunity cost of the convertible noteholders for foregoing the debt portion of the instrument. Each outcome was probability-weighted based on future estimates. Upon the closing of the IPO in October 2021, the 2018, 2019, and 2020 Notes converted into Series D redeemable convertible preferred stock pursuant to automatic conversion feature of the convertible notes. Due to the conversion of the 2018, 2019, and 2020 Notes, the associated derivative liabilities were revalued and extinguished with the change in fair value recorded as other income in the Company’s Statement of Operations. The change in fair value of the redeemable convertible preferred stock warrant liability, derivative liabilities and contingent consideration liability are summarized below (in thousands): Redeemable Derivative Contingent Beginning fair value, December 31, 2020 $ 42 $ 38,007 $ 23,667 Change in fair value 582 6,121 ( 204 ) Ending fair value, March 31, 2021 624 44,128 23,463 Change in fair value ( 50 ) 2,019 1,121 Ending fair value, June 30, 2021 574 46,147 24,584 Change in fair value 3 ( 23,383 ) ( 137 ) Ending fair value, September 30, 2021 $ 577 $ 22,764 $ 24,447 Contingent Beginning fair value, December 31, 2021 $ 14,094 Change in fair value ( 151 ) Payment ( 5,000 ) Ending fair value, March 31, 2022 8,943 Change in fair value ( 3,943 ) Ending fair value, June 30, 2022 5,000 Change in fair value — Ending fair value, September 30, 2022 $ 5,000

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2022
Balance Sheet Components [Abstract]
Balance Sheet Components	6. Balance Sheet Components Cash and cash equivalents The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2022 2021 Cash $ 2,070 $ 2,086 Cash equivalents: Money market funds 13,042 38,522 Total cash and cash equivalents $ 15,112 $ 40,608 Inventory Inventory consists of the following (in thousands): September 30, December 31, 2022 2021 Finished goods $ 8,079 $ 9,495 Component materials 8,924 6,187 Total inventory $ 17,003 $ 15,682 Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, 2022 2021 Prepaid expenses $ 1,735 $ 1,264 Prepaid insurance 411 2,726 Other current assets 119 149 Total prepaid expenses and other current assets $ 2,265 $ 4,139 Property and equipment, net Property and equipment, net consist of the following (in thousands): September 30, December 31, Useful life (years) 2022 2021 Computers and software 2 $ 407 $ 730 Machinery and equipment 3 658 997 Furniture and fixtures 7 48 48 Tools and dies 2 903 941 Construction in progress — 317 428 Equipment under customer usage agreements 3 12,714 10,612 Leasehold improvements Lesser of useful life or lease term 155 155 15,202 13,911 Less: accumulated depreciation and amortization ( 10,171 ) ( 9,317 ) Property and equipment, net $ 5,031 $ 4,594 Depreciation and amortization expense on property and equipment was $ 0.6 million for the three-month periods ended on September 30, 2022 and 2021. Of this amount approximately $ 0.6 million for the three-month periods ended on September 30, 2022 and 2021, was related to equipment under customer usage agreements recorded to cost of goods sold. Depreciation and amortization expense on property and equipment was $ 1.9 million and $ 1.8 million for the nine-month periods ended on September 30, 2022 and 2021, respectively. Of this amount approximately $ 1.7 million, and $ 1.6 million for the nine-month periods ended on September 30, 2022 and 2021, respectively, was related to equipment under customer usage agreements recorded to cost of goods sold. Intangible asset, net Intangible asset, net consist of the following (in thousands): September 30, 2022 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 1,450 ) $ 2,519 Developed technology 30,819 ( 7,320 ) 23,499 Customer relationships 13,466 ( 10,661 ) 2,805 Other intangible assets 61 — 61 Total intangible assets $ 48,315 $ ( 19,431 ) $ 28,884 December 31, 2021 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 992 ) $ 2,977 Developed technology 30,819 ( 5,008 ) 25,811 Customer relationships 13,466 ( 7,294 ) 6,172 Other intangible assets 10 — 10 Total intangible assets $ 48,264 $ ( 13,294 ) $ 34,970 Amortization expense on intangible assets was $ 2.0 million for the three-month periods ended on September 30, 2022 and 2021. Amortization expense on intangible assets was $ 6.1 million for the nine-month periods ended on September 30, 2022 and 2021. Future amortization expense of intangible assets related to the acquisition of assets from Boston Scientific Corporation as of September 30, 2022 is as follows (in thousands): 2022 (remaining three months) $ 2,045 2023 5,376 2024 3,693 2025 3,693 Thereafter 14,016 Total $ 28,823 Accrued compensation Accrued compensation consists of the following (in thousands): September 30, December 31, 2022 2021 Accrued vacation $ 1,468 $ 1,469 Accrued bonuses 1,805 1,307 Accrued commissions 690 665 Other accrued personnel related expenses 261 77 Total accrued compensation $ 4,224 $ 3,518 Accrued liabilities Accrued liabilities consist of the following (in thousands): September 30, December 31, 2022 2021 Accrual for litigation $ 7,420 $ 7,203 Accrued professional fees 648 974 Accrued sales and use taxes 319 657 Deferred rent - 277 Accrual for inventory in transit 253 119 Contract liability 362 206 Accrued interest expense 261 189 Others 1,121 1,037 Total accrued liabilities $ 10,384 $ 10,662

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	7. Debt CIBC term loan On October 8, 2021, the Company entered into a Loan and Security Agreement (the CIBC Agreement) with Canadian Imperial Bank of Commerce (CIBC), which provides for a senior secured term loan in an aggregate principal amount of $ 40.0 million (the CIBC Loan), the full amount of which was funded at the closing of the CIBC Agreement. The CIBC Loan provides for 24 months of interest-only payments followed by 36 equal monthly payments of principal, plus accrued and unpaid interest, with the final obligations due and payable in full on October 8, 2026. The CIBC Loan accrues interest at a floating rate equal to 2.5% above the prime rate, and the interest is payable monthly in arrears. As of September 30, 2022 , the CIBC Loan had an annual effective interest rate of 10.0 % per annum. The Company may prepay the CIBC Loan in whole or in parts. Obligations under the CIBC Agreement are secured by substantially all of the Company’s assets. The CIBC Agreement contains customary affirmative and negative covenants as well as financial covenants that require the Company to maintain minimum revenue and minimum cash thresholds. The CIBC Agreement contains customary events of default subject to customary cure periods for certain defaults that include, among others, non-payment defaults, inaccuracy of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness, bankruptcy, and insolvency events with respect to the Company, and material judgements. Upon the occurrence and during the continuance of an event of default, CIBC may accelerate the Company’s obligations under the CIBC Agreement, increase the applicable interest rate by 5.0% and exercise other remedies provided for under the CIBC Agreement and applicable law. The CIBC Loan consists of the following (in thousands): September 30, December 31, 2022 2021 Term loan principal $ 40,000 $ 40,000 Less: Debt discount and debt issuance cost ( 729 ) ( 915 ) Accrued interest 261 189 Term loan $ 39,532 $ 39,274 The Company paid $ 1.0 million in fees to CIBC and third parties which is reflected as a debt discount and debt issuance costs, respectively, and are being accreted over the life of the term loan using the effective interest method. During the three- and nine-month periods ended September 30, 2022 the Company recorded interest expense of $ 0.9 million and $ 2.2 million, respectively, which includes interest expense related to accretion of debt discount and debt issuance costs of the CIBC Loan of $ 0.1 million and $ 0.2 million, respectively. During the three- and nine-month periods ended September 30, 2021 the Company recorded interest expense of $ 1.9 million and $ 5.9 million, respectively, which includes interest expense related to accretion of debt discount, debt issuance costs and exit fee of the Ares Loan of $ 0.9 million and $ 1.9 million, respectively. During the three months ended December 31, 2021, the Company repaid its entire obligation under the Ares Loan. During the three- and nine-month periods ended September 30, 2021 the Company recorded interest expense of $ 1.9 million and $ 5.9 million, respectively, on the 2018, 2019 and 2020 Notes, which includes interest expense related to amortization of debt discount of the 2018, 2019 and 2020 Notes of $ 0.6 million and $ 1.7 million, respectively. In three months ended December 31, 2021, the Company converted outstanding principal and accrued interest of the convertible notes into shares of redeemable convertible preferred stock. Contractual maturities of financing obligations As of September 30, 2022, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2022 (remaining three months) $ 856 2023 5,654 2024 15,765 2025 14,627 2026 12,405 Total 49,307 Less: unamortized debt discounts and issuance costs ( 729 ) Less: interest ( 9,046 ) Term loan $ 39,532

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating lease The Company's corporate headquarters, research and development facilities, manufacturing and distribution center are located in Santa Clara, CA (Santa Clara facility) and are subject to a non-cancellable operating sublease that terminates in May 2023. On July 29, 2022, the Company entered into a new operating lease arrangement (Mission Park Lease) for its current Santa Clara facility. The new lease commences on June 1, 2023 and will expire on May 31, 2028 and contains monthly base rent payments of approximately $ 88,341 that increase annually by 3 % over the term of the lease. In addition to the base rent, the Company will reimburse the landlord for certain operating expenses under the terms of the new lease. The Company will establish a letter of credit for approximately $ 0.3 million as collateral for its new lease in favor of the new lessor. The $ 0.3 million have been recorded as restricted cash on the balance sheet as of September 30, 2022. The Company recognized rent expense of $ 0.2 million and $ 0.5 million for each of the three- and nine-month periods ended on September 30, 2022, and $ 0.2 million and $ 0.6 million for the three- and nine-months periods ended September 30, 2021, respectively. The Company adopted ASC 842 and the related amendments on January 1, 2022 . The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the nine-month period ended September 30, 2022 : For nine Months Ended Lease Cost (in thousands) Operating lease cost $ 490 Short-term lease cost — Variable lease cost 186 Total lease cost $ 676 Other Information Operating cash flows used for lease liabilities $ 631 Right of use asset acquired under operating lease on the adoption of ASC 842 $ 429 Weighted average remaining lease term (in years) 0.7 Weighted average incremental borrowing rate 4.0 % As of September 30, 2022 , operating lease right of use assets were $ 0.4 million and operating lease liabilities were $ 0.6 million. The Company has no finance leases. The maturities of the operating lease liabilities as of September 30, 2022 were as follows (in thousands): 2022 (remaining three months) $ 215 2023 358 Total undiscounted lease payments 573 Less: imputed interest 8 Total operating lease liability 565 Less: current portion 565 Operating lease liability, net of current maturities $ - The future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2021 under ASC 840 were as follows (in thousands): 2022 $ 846 2023 358 Total minimum lease payments $ 1,204 The Company maintains letters of credit of $ 0.5 million in connection with the Company’s office leases in Santa Clara (Santa Clara Lease). As of September 30, 2022 and December 31, 2021, the cash amount associated with the current Santa Clara Lease is recorded as restricted cash on the balance sheet. Indemnification The Company enters into indemnification provisions under its agreements with other companies in the ordinary course of business, including business partners and contractors. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party as a result of the Company’s activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. The Company maintains commercial general liability insurance and products liability insurance to offset certain of its potential liabilities under these indemnification provisions. Litigation The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether such information warrants the recording of additional expense. In November 2015, Hologic, Inc. and Cytyc Surgical Products, LLC (collectively, Hologic) filed a complaint against the Company alleging infringement of four patents. Hologic ultimately dropped two of the four asserted patents and two patents remained in the case: U.S. Patent Nos. 6,872,183 (“the ’183 patent”) and 9,095,348 (“the ’348 patent”). On December 15, 2017, the Patent Office found the asserted claims of the ’183 patent to be invalid. The District Court denied Minerva’s motion to dismiss or stay the case as to that patent pending Hologic's appeal. A few weeks before trial, in June 2018, the District Court held on summary judgment that Minerva infringed the ’183 and ’348 patents. In that same summary judgment order, the District Court also granted Hologic’s motion to deny Minerva’s 35 U.S.C, §112 defenses based on the doctrine of assignor estoppel. The parties went to trial in July 2018 on the issues of damages and willfulness. Hologic sought over $ 16.0 million in damages. On July 27, 2018, a Delaware jury returned a verdict finding the Company did not willfully infringe and awarded Hologic $ 4.8 million in damages for lost profits and for royalties not included in the lost profits—less than a third of Hologic’s damages request. Based on the result of the trial in July 2018 with Hologic, the Company recorded an accrual for potential legal losses of $ 4.8 million as of December 31, 2017 with a corresponding expense within general and administrative expenses. On April 19, 2019, Court of Appeals for the Federal Circuit (Federal Circuit) unanimously affirmed the invalidity of the ’183 patent, which was the only patent on which Hologic was relying in its motion for a permanent injunction as the ’348 patent had already expired in November 2018. As a consequence, the District Court denied Hologic’s post-trial motion for a permanent injunction. The District Court issued its Final Judgment on June 3, 2019.In July 2019, the Company appealed to the Federal Circuit. At the time of filing the appeal, the updated damages calculation totaled $ 7.1 million (supplemental damages and interest) and the related cash balance was restricted from withdrawal. A surety bond was generated and filed along with the appeal documents and included in restricted cash in the balance sheet. The additional damages were accrued for as of December 31, 2018. On April 22, 2020, the Federal Circuit affirmed the verdict of the $ 7.1 million in total damages and found that Minerva was precluded from contesting the validity of the one remaining ’348 patent based on the doctrine of assignor estoppel. The Federal Circuit remanded to the District Court. On August 28, 2020, the District Court issued its amended final judgment pursuant to the Federal Circuit’s remand. The District Court amended the award to Hologic as follows: (i) damages in the amount of $ 4,787,668 plus prejudgment interest in the amount of $ 270,533 and post-judgment interest at the statutory rate of 2.44 % from August 13, 2018 until such time as the judgment is paid; and (ii) supplemental damages in the amount of $ 1,629,304 from April 1, 2018 through November 19, 2018, plus pre-judgment interest in the amount of $ 79,073 and post-judgment interest at the statutory rate of 2.28 % from June 3, 2019 until such time as the judgment is paid. The District Court also stayed all actions and proceedings to execute the amended final judgment pending exhaustion of all appeals. In September 2020, the Company filed a petition for certiorari with the U.S. Supreme Court, which was granted. On November 11, 2020, the Company increased the bond amount to $ 7,203,414 to sufficiently cover the post-judgment interest accrued during the pendency of the appeal. The bond amount was subsequently increased to $ 7,420,507 due to accrued interest. On June 29, 2021, the U.S. Supreme Court put constraints on the proper application of assignor estoppel, and vacated and remanded to the Federal Circuit to determine whether assignor estoppel applies to Minerva under the new criteria, or can pursue its challenge to the validity of the ’348 patent. On remand, the Federal Circuit heard oral arguments on January 27, 2022. Following remand, on August 11, 2022, the Federal Circuit determined that assignor estoppel still applies and bars Minerva from contesting the validity of the ’348 patent in District Court. On September 9, 2022, Minerva filed a Petition for rehearing en banc . As of September 30, 2022, that Petition remained pending. On July 8, 2020, Hologic sued the Company for willful infringement of the same ’348 patent in the U.S. District Court for the District of Delaware, alleging that Minerva's new EAS Handpiece also infringed the patent for the approximately five month period before that patent expired. The Company has answered, denying infringement and willfulness and alleges that the patent was invalid prior to expiry. Due to COVID-19, the case was stayed twice for 60 days. On April 6, 2021, the District Court granted the Minerva’s motion to stay this case until all appeals have been exhausted relating to the ’348 patent (see above). Recently, the court lifted the stay and set a status conference for November 1, 2022. The stay may be re-imposed if Minerva’s above Petition for rehearing en banc is granted. In April 2017, the Company sued Hologic for willful infringement of a Company patent (U.S. Patent No. 9,186,208 (“the ’208 patent”) in the U.S. District Court for the Northern District of California. Hologic has answered, denying infringement and willfulness and alleging invalidity of the patent. The Company sought a preliminary injunction and that motion was denied. This matter was thereafter transferred to the U.S. District Court for the District of Delaware, where it has been assigned to the same judge presiding over the Hologic complaints. Due to COVID-19, the July 2020 trial date was delayed. On July 20, 2021, the District Court granted Hologic’s motion excluding certain expert opinions regarding infringement. On July 23, 2021, the District Court found on summary judgment that the Company’s ’208 patent is invalid, dismissed the case and entered judgment. On August 24, 2021, the Company appealed to the Federal Circuit. Hologic’s response brief was filed on March 4, 2022, The Company's response was filed on April 12, 2022. A decision on this appeal proceeding in the Federal Circuit is expected to take at least several months.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company did no t record an income tax provision for the three- and nine-month periods ended September 30, 2022 and 2021. The Company’s net deferred tax assets are fully offset by a valuation allowance, as the Company believes it is more likely than not the benefit will not be realized.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Common stock warrants As of September 30, 2022, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842 Shares reserved for future issuance The Company has shares of common stock reserved for future issuances as follows: September 30, December, 31 2022 2021 Warrants to purchase common stock 77,842 77,842 Common stock options issued and outstanding 2,183,311 2,175,685 Common stock available for future grants 472,104 1,934,095 Restricted stock units issued and outstanding 1,703,213 394,750 Common stock available for ESPP 401,164 401,164 2008 Stock Plan and 2021 Equity Incentive Plan, as amended (the 2021 and 2008 Plan) A summary of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, December 31, 2021 2,175,685 $ 9.27 8.7 $ 2,856 Options granted 189,800 $ 3.27 Options exercised ( 56,964 ) $ 0.61 Options forfeited or cancelled ( 125,210 ) $ 8.71 Outstanding, September 30, 2022 2,183,311 $ 9.00 8.1 $ 99 Shares exercisable September 30, 2022 1,577,934 $ 9.66 7.8 $ 81 Vested and expected to vest, September 30, 2022 2,183,311 $ 9.00 8.1 $ 99 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money as of September 30, 2022 and December 31, 2021. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2022 and 2021 was de minimis and zero , respectively. The total fair value of options that vested during the nine months ended September 30, 2022 and 2021 was $ 2.9 million and $ 5.1 million, respectively. The options granted during the nine months ended September 30, 2022 and 2021 had a weighted-average per share grant-date fair value of $ 2.11 per share and $ 7.07 per share, respectively. As of September 30, 2022 , the total unrecognized stock-based compensation expense related to unvested stock options was $ 5.9 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.2 years . Early exercise of stock options The terms of the 2008 Plan permit the exercise of certain options granted under the 2008 Plan prior to vesting, subject to required approvals. The shares are subject to the Company’s lapsing repurchase right upon termination of employment at the original purchase price. The proceeds initially are recorded in accrued current liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the nine months ended September 30, 2022 and 2021, the Company had no repurchases of common stock. As of September 30, 2022 and December 31, 2021, there were 227,507 shares and 377,709 shares that were subject to repurchase, respectively. The aggregate exercise prices of early exercised shares as of September 30, 2022 and December 31, 2021 were $ 0.1 million and $ 0.2 million, respectively, which were recorded in other current liabilities on the balance sheets. Restricted Stock Units A summary of RSU activity is set forth below (in thousands, except share and per share data): A summary of RSU activity is set forth below (in thousands, except share and per share data): Number of Weighted Average Grant Date Fair Value Unvested, January 1, 2022 394,750 $ 5.17 Granted 1,485,629 $ 2.57 Exercised/released ( 88,938 ) $ 2.85 Forfeited or cancelled ( 88,228 ) $ 3.09 Unvested, September 30, 2022 1,703,213 $ 3.13 As of September 30, 2022 , the total unrecognized stock-based compensation expense related to unvested restricted stock units was $ 3.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.8 years. 2021 Employee Stock Purchase Plan, as amended (ESPP) In October 2021, the board of directors adopted, and the stockholders approved the Company’s 2021 Employee Stock Purchase Plan (ESPP), which became effective on October 20, 2021, the business day prior to the effectiveness of the registration statement relating to the IPO. A total of 401,164 shares of common stock were initially reserved for issuance under the ESPP. The Company’s compensation committee administers the ESPP. Additional shares can be added to the ESPP at the beginning of each year as allowed by the plan. The ESPP provides for consecutive offering periods that typically have a duration of approximately twelve months in length and are comprised of two sequential purchase periods, or tranches, of approximately six months in length. The offering periods are scheduled to start on the first trading day on or after June 1 and December 1 of each year. The first offering period commenced on June 1, 2022 and is scheduled to end on the first trading day on or before May 31, 2023 and a total of 468,959 predicted shares were committed under the ESPP based on the June 1, 2022 employee enrollment. The ESPP provides eligible employees with an opportunity to purchase shares of the Company’s common stock through payroll deductions of up to 15 % of their eligible compensation. A participant may purchase up to a maximum of 10,000 shares of common stock within the IRS limit of $ 25,000 grant date share value during a purchase period. Amounts deducted and accumulated by the participant are used to purchase shares of common stock at the end of each six-month purchase period. The purchase price of the shares shall be 85 % of the lower of the fair market value of the common stock on (i) the first trading day of the applicable offering period and (ii) the last trading day of each purchase period in the related offering period. Participants may end their participation at any time during an offering period and will be paid their accrued contributions that have not yet been used to purchase shares of common stock. Participation ends automatically upon termination of employment. The fair value of the predicted share purchase rights granted under the ESPP upon the commencement of the offering period was estimated on the date of grant using the Black-Scholes option pricing model applying the following assumptions as of June 1, 2022: (i) risk-free interest rate 2.15 %, (ii) dividend rate 0 %, (iii) expected terms 0.5 years and 1.0 years, and (iv) volatility 74.52 % and 65.14 %, for the two tranches, respectively. Compensation expense of approximately $ 0.1 million and $ 0.2 million was recorded into the condensed statement of operations for the three-and nine-months ended September 30, 2022. As of September 30, 2022, the total unrecognized compensation cost related to the ESPP tranches was less than $ 0.1 million and $ 0.2 million, which will be amortized for the two tranches over weighted-average periods of approximately 0.1 and 1.0 years, respectively. Stock-based compensation associated with awards to employees and non-employees Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of goods sold $ 97 $ 66 $ 240 $ 236 Sales and marketing 729 406 1,918 1,701 Research and development 4 8 33 127 General and administrative 1,147 595 2,985 3,620 Total $ 1,977 $ 1,075 $ 5,176 $ 5,684 The above stock-based compensation expense related to the following equity-based awards (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options $ 954 $ 1,075 2,969 5,684 RSU 852 — 1,982 — ESPP 171 — 225 — Total $ 1,977 $ 1,075 $ 5,176 $ 5,684 The Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected dividends 0 % 0 % 0 % 0 % Expected volatility 72.20 % 73.3 % - 75.0 % 70.8 %- 72.2 % 72.9 % - 75.9 % Risk-free interest rate 2.8 % 0.9 % - 1.1 % 1.9 %- 3.0 % 0.6 % - 1.1 % Expected term 6 years 5 - 6 years 6 years 5 - 6 years

Net Loss Per Share Attributable

Net Loss Per Share Attributable To Common Stockholders	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	11. Net Loss Per Share Attributable To Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss attributable to common stockholders by the weighted-average number ores of common stock outstanding for the period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share amounts) 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders $ ( 11,329 ) $ ( 3,225 ) $ ( 27,867 ) $ ( 32,272 ) Denominator: Weighted-average common stock outstanding 28,611,045 2,798,146 28,553,949 2,145,733 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.40 ) $ ( 1.15 ) $ ( 0.98 ) $ ( 15.04 ) The following table indicates the number of potentially dilutive securities excluded from the calculation of Diluted net income (loss) per common share because their inclusion would have been anti-dilutive. The number of shares is as of the end of each period: September 30, 2022 2021 Redeemable convertible preferred stock — 12,397,838 Redeemable convertible preferred stock warrants — 77,842 Common stock warrants 77,842 — Unvested early exercised common stock options 227,507 410,788 Options to purchase common stock 2,183,311 2,170,894 Unvested restricted stock units 1,703,213 —

Employee Benefit Plan

Employee Benefit Plan	9 Months Ended
	Sep. 30, 2022
Disclosure Text Block Supplement [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan In 2012, the Company implemented a tax deferred savings plan, commonly referred to as a 401(k) plan. Employee contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. There has been no Company matching of employee contributions to the plan through September 30, 2022 .

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On November 10, 2022, the Court of Appeals for the Federal Circuit (CAFC) issued an order denying Minerva’s Petition for Rehearing in the initial patent case filed by Hologic in November 2015. On November 17, 2022, the Federal Circuit CAFC will issue its mandate, effectively ending the CAFC appeal, at which point Minerva will be obligated to pay the bond amount of approximately $ 7.4 million to Hologic. It also means that the follow-on patent case filed by Hologic in July of 2019, which seeks damages for approximately five months of sales of Minerva’s redesigned handpiece and is based on the same patent that expired in November 2018 as in the first case, will proceed towards trial currently set for August 21, 2023, in the District of Delaware.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP). Certain prior year amounts have been reclassified to conform to the current year presentation.
Reverse Stock Split	Reverse Stock Split On October 14, 2021, the Company effected a 1 -for-6.046 reverse stock split of its outstanding common stock and redeemable convertible preferred stock. Upon the effectiveness of the reverse stock split, all issued and outstanding shares of common stock, options to purchase common stock, warrants, instruments convertible to shares, redeemable convertible preferred stock and related share data and per share amounts contained in the accompanying financial statements were retroactively revised to reflect this reverse stock split for all periods presented. The par value of the authorized stock was not adjusted as a result of the reverse stock split.
Unaudited interim financial information	Unaudited interim financial information The accompanying condensed balance sheet as of September 30, 2022, the condensed statements of operations, the condensed statements of redeemable convertible preferred stock and stockholders’ equity and condensed statements of cash flows for the periods ended September 30, 2022 and 2021 are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the 2021 audited annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2022 and the results of its operations and its cash flows for the three- and nine-month periods ended September 30, 2022 and 2021. The financial data and other information disclosed in these notes related to the three- and nine-month periods ended September 30, 2022 and 2021 are also unaudited. The results for the three- and nine-month periods ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. The balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the interim condensed financial statements. These unaudited interim condensed financial statements should be read in conjunction with the audited annual financial statements and related notes. The significant accounting policies used in the preparation of the unaudited condensed financial statements for the three- and nine-month periods ended September 30, 2022 and 2021, are consistent with those discussed in Note 2 to the audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 23, 2022. There have been no significant changes in the significant accounting policies or critical accounting estimates since December 31, 2021, except for the accounting policy related to ASU 2016-02, Leases discussed below.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, including definite-lived intangible assets, revaluation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, contingent consideration liability, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, deferred tax assets and related valuation allowances, impact of contingencies and the Company’s incremental borrowing rate used to calculate lease assets .
Fair value of financial instruments	Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates its fair value and is classified as a Level 2 liability.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At September 30, 2022 and 2021, and for the periods then ended, no customer accounted for more than 10.0% of accounts receivable or revenue.
Concentration of suppliers	Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect our results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event.
Lease	Lease Prior to January 1, 2022, the Company met the requirements to account for leases of its facilities as operating leases under ASC 840. The Company recognized rent expense on a straight-line basis over the non-cancellable lease term. Where leases contain escalation clauses, rent abatements or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applied them in the determination of straight-line rent expense over the lease term. The Company recorded the difference between the rent paid and the straight-line rent as a deferred rent liability. Upon adoption of ASU 2016-02, Leases (Topic 842) , and the related amendments (ASC 842), on January 1, 2022, the Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the Company's balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. For a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company’s statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of twelve months or less. Variable lease payments are expensed as incurred. Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders, by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was considered a participating security because it participated in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock did not have a contractual obligation to share in the Company’s losses for the three- and nine-month periods ended September 30, 2021. Prior to the three- and nine-month periods ended September 30, 2022 all the redeemable convertible preferred stock were converted into shares of common stock. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for the three- and nine-month periods ended September 30, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for all periods presented.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Disaggregation of revenue Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Minerva ES 46.8 % 46.1 % 45.1 % 46.8 % Genesys HTA 28.4 % 31.2 % 29.5 % 32.0 % Symphion 24.1 % 22.0 % 24.8 % 20.2 % Other 0.7 % 0.7 % 0.6 % 1.0 % 100 % 100 % 100 % 100 %
Schedule of Contract Balance	The Company’s contract balances consist of the following (in thousands): September 30, December 31, 2022 2021 Accounts receivable, net $ 6,791 $ 7,292 Contract liability—current (see "Note 6") $ 362 $ 206

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 13,042 $ — $ — $ 13,042 Total financial assets $ 13,042 $ — $ — $ 13,042 Liability: Contingent consideration liability $ — $ — $ 5,000 $ 5,000 Total financial liabilities $ — $ — $ 5,000 $ 5,000 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 38,522 $ — $ — $ 38,522 Total financial assets $ 38,522 $ — $ — $ 38,522 Liability: Contingent consideration liability $ — $ — $ 14,094 $ 14,094 Total financial liabilities $ — $ — $ 14,094 $ 14,094
Schedule of Change in Fair Value of the Redeemable Convertible Preferred Stock Warrant Liability, Derivative Liabilities and Contingent Consideration Liability	The change in fair value of the redeemable convertible preferred stock warrant liability, derivative liabilities and contingent consideration liability are summarized below (in thousands): Redeemable Derivative Contingent Beginning fair value, December 31, 2020 $ 42 $ 38,007 $ 23,667 Change in fair value 582 6,121 ( 204 ) Ending fair value, March 31, 2021 624 44,128 23,463 Change in fair value ( 50 ) 2,019 1,121 Ending fair value, June 30, 2021 574 46,147 24,584 Change in fair value 3 ( 23,383 ) ( 137 ) Ending fair value, September 30, 2021 $ 577 $ 22,764 $ 24,447 Contingent Beginning fair value, December 31, 2021 $ 14,094 Change in fair value ( 151 ) Payment ( 5,000 ) Ending fair value, March 31, 2022 8,943 Change in fair value ( 3,943 ) Ending fair value, June 30, 2022 5,000 Change in fair value — Ending fair value, September 30, 2022 $ 5,000

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2022
Balance Sheet Components [Abstract]
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2022 2021 Cash $ 2,070 $ 2,086 Cash equivalents: Money market funds 13,042 38,522 Total cash and cash equivalents $ 15,112 $ 40,608
Schedule of Inventory	Inventory consists of the following (in thousands): September 30, December 31, 2022 2021 Finished goods $ 8,079 $ 9,495 Component materials 8,924 6,187 Total inventory $ 17,003 $ 15,682
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, 2022 2021 Prepaid expenses $ 1,735 $ 1,264 Prepaid insurance 411 2,726 Other current assets 119 149 Total prepaid expenses and other current assets $ 2,265 $ 4,139
Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): September 30, December 31, Useful life (years) 2022 2021 Computers and software 2 $ 407 $ 730 Machinery and equipment 3 658 997 Furniture and fixtures 7 48 48 Tools and dies 2 903 941 Construction in progress — 317 428 Equipment under customer usage agreements 3 12,714 10,612 Leasehold improvements Lesser of useful life or lease term 155 155 15,202 13,911 Less: accumulated depreciation and amortization ( 10,171 ) ( 9,317 ) Property and equipment, net $ 5,031 $ 4,594
Schedule of Intangible Assets, Net	Intangible asset, net consist of the following (in thousands): September 30, 2022 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 1,450 ) $ 2,519 Developed technology 30,819 ( 7,320 ) 23,499 Customer relationships 13,466 ( 10,661 ) 2,805 Other intangible assets 61 — 61 Total intangible assets $ 48,315 $ ( 19,431 ) $ 28,884 December 31, 2021 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 992 ) $ 2,977 Developed technology 30,819 ( 5,008 ) 25,811 Customer relationships 13,466 ( 7,294 ) 6,172 Other intangible assets 10 — 10 Total intangible assets $ 48,264 $ ( 13,294 ) $ 34,970
Schedule of Future Amortization Expense of Intangible Assets Related to Acqusition of Assets	Future amortization expense of intangible assets related to the acquisition of assets from Boston Scientific Corporation as of September 30, 2022 is as follows (in thousands): 2022 (remaining three months) $ 2,045 2023 5,376 2024 3,693 2025 3,693 Thereafter 14,016 Total $ 28,823
Schedule of Accrued Compensation	Accrued compensation consists of the following (in thousands): September 30, December 31, 2022 2021 Accrued vacation $ 1,468 $ 1,469 Accrued bonuses 1,805 1,307 Accrued commissions 690 665 Other accrued personnel related expenses 261 77 Total accrued compensation $ 4,224 $ 3,518
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): September 30, December 31, 2022 2021 Accrual for litigation $ 7,420 $ 7,203 Accrued professional fees 648 974 Accrued sales and use taxes 319 657 Deferred rent - 277 Accrual for inventory in transit 253 119 Contract liability 362 206 Accrued interest expense 261 189 Others 1,121 1,037 Total accrued liabilities $ 10,384 $ 10,662

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The CIBC Loan consists of the following (in thousands): September 30, December 31, 2022 2021 Term loan principal $ 40,000 $ 40,000 Less: Debt discount and debt issuance cost ( 729 ) ( 915 ) Accrued interest 261 189 Term loan $ 39,532 $ 39,274
Schedule of Contractual Maturities of Financing Obligations	As of September 30, 2022, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2022 (remaining three months) $ 856 2023 5,654 2024 15,765 2025 14,627 2026 12,405 Total 49,307 Less: unamortized debt discounts and issuance costs ( 729 ) Less: interest ( 9,046 ) Term loan $ 39,532

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Lease Costs	The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the nine-month period ended September 30, 2022 : For nine Months Ended Lease Cost (in thousands) Operating lease cost $ 490 Short-term lease cost — Variable lease cost 186 Total lease cost $ 676 Other Information Operating cash flows used for lease liabilities $ 631 Right of use asset acquired under operating lease on the adoption of ASC 842 $ 429 Weighted average remaining lease term (in years) 0.7 Weighted average incremental borrowing rate 4.0 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of the operating lease liabilities as of September 30, 2022 were as follows (in thousands): 2022 (remaining three months) $ 215 2023 358 Total undiscounted lease payments 573 Less: imputed interest 8 Total operating lease liability 565 Less: current portion 565 Operating lease liability, net of current maturities $ -
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2021 under ASC 840 were as follows (in thousands): 2022 $ 846 2023 358 Total minimum lease payments $ 1,204

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of common stock warrants	Common stock warrants As of September 30, 2022, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842
Schedule of Shares Reserved for Future Issuance	The Company has shares of common stock reserved for future issuances as follows: September 30, December, 31 2022 2021 Warrants to purchase common stock 77,842 77,842 Common stock options issued and outstanding 2,183,311 2,175,685 Common stock available for future grants 472,104 1,934,095 Restricted stock units issued and outstanding 1,703,213 394,750 Common stock available for ESPP 401,164 401,164
Schedule of Stock Option Activity	A summary of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, December 31, 2021 2,175,685 $ 9.27 8.7 $ 2,856 Options granted 189,800 $ 3.27 Options exercised ( 56,964 ) $ 0.61 Options forfeited or cancelled ( 125,210 ) $ 8.71 Outstanding, September 30, 2022 2,183,311 $ 9.00 8.1 $ 99 Shares exercisable September 30, 2022 1,577,934 $ 9.66 7.8 $ 81 Vested and expected to vest, September 30, 2022 2,183,311 $ 9.00 8.1 $ 99
Schedule of Restricted Stock Units Activity	A summary of RSU activity is set forth below (in thousands, except share and per share data): A summary of RSU activity is set forth below (in thousands, except share and per share data): Number of Weighted Average Grant Date Fair Value Unvested, January 1, 2022 394,750 $ 5.17 Granted 1,485,629 $ 2.57 Exercised/released ( 88,938 ) $ 2.85 Forfeited or cancelled ( 88,228 ) $ 3.09 Unvested, September 30, 2022 1,703,213 $ 3.13
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of goods sold $ 97 $ 66 $ 240 $ 236 Sales and marketing 729 406 1,918 1,701 Research and development 4 8 33 127 General and administrative 1,147 595 2,985 3,620 Total $ 1,977 $ 1,075 $ 5,176 $ 5,684 The above stock-based compensation expense related to the following equity-based awards (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options $ 954 $ 1,075 2,969 5,684 RSU 852 — 1,982 — ESPP 171 — 225 — Total $ 1,977 $ 1,075 $ 5,176 $ 5,684
Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions	The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected dividends 0 % 0 % 0 % 0 % Expected volatility 72.20 % 73.3 % - 75.0 % 70.8 %- 72.2 % 72.9 % - 75.9 % Risk-free interest rate 2.8 % 0.9 % - 1.1 % 1.9 %- 3.0 % 0.6 % - 1.1 % Expected term 6 years 5 - 6 years 6 years 5 - 6 years

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable To Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss attributable to common stockholders by the weighted-average number ores of common stock outstanding for the period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share amounts) 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders $ ( 11,329 ) $ ( 3,225 ) $ ( 27,867 ) $ ( 32,272 ) Denominator: Weighted-average common stock outstanding 28,611,045 2,798,146 28,553,949 2,145,733 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.40 ) $ ( 1.15 ) $ ( 0.98 ) $ ( 15.04 )
Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following table indicates the number of potentially dilutive securities excluded from the calculation of Diluted net income (loss) per common share because their inclusion would have been anti-dilutive. The number of shares is as of the end of each period: September 30, 2022 2021 Redeemable convertible preferred stock — 12,397,838 Redeemable convertible preferred stock warrants — 77,842 Common stock warrants 77,842 — Unvested early exercised common stock options 227,507 410,788 Options to purchase common stock 2,183,311 2,170,894 Unvested restricted stock units 1,703,213 —

Formation and Business of the_2

Formation and Business of the Company - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended						9 Months Ended
	Oct. 21, 2021	Oct. 20, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares authorized	100,000,000		100,000,000						100,000,000		100,000,000
Common stock, par value	$ 0.001		$ 0.001						$ 0.001		$ 0.001
Preferred stock, shares authorized	5,000,000		5,000,000						5,000,000		5,000,000
Preferred stock, par value	$ 0.001		$ 0.001						$ 0.001		$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion		19,404,066
Net Loss			$ 11,329	$ 5,613	$ 10,925	$ 3,225	$ 14,099	$ 14,948	$ 27,867	$ 32,272
Accumulated deficit			(277,423)						(277,423)		$ (249,556)
Cash and cash equivalents			$ 15,112						$ 15,112		$ 40,608
Convertible Promissory Notes
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate outstanding principal and accrued interest of convertible promissory notes		$ 79,200
Initial Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred offering costs	$ 3,200
Redeemable Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of preferred stock		7,006,228
Conversion price per share		$ 11.31
Common Stock | Initial Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares sold and issued	6,250,000
Shares issued offering price per share	$ 12
Aggregate gross proceeds	$ 75,000
Net proceeds after deducting underwriting discounts and commissions	$ 69,800

Summary of significant accoun_3

Summary of significant accounting policies - Additional Information (Details)		9 Months Ended
	Oct. 14, 2021	Sep. 30, 2022 Customer	Sep. 30, 2021 Customer
Financing Receivable Impaired [Line Items]
Reverse stock split	1-for-6.046
Reverse stock split ratio	0.165
Number of customer accounted for accounts receivable or revenue		0	0

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Details) $ in Millions	Sep. 30, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expected Operating Lease Right of Use Assets	$ 0.9
Expected operating lease liability	1.2
Expected derecognized deferred rent	$ 0.3
ASC 842
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue	100%	100%	100%	100%
Minerva ES
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue	46.80%	46.10%	45.10%	46.80%
Genesys HTA
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue	28.40%	31.20%	29.50%	32%
Symphion
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue	24.10%	22%	24.80%	20.20%
Other
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue	0.70%	0.70%	0.60%	1%

Revenue - Additional Informatio

Revenue - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Percentage of revenue subject to point-in-time recognition	99.90%	99%	99.90%	99%
Minimum percentage of sale extended warranties on capital equipment	0.10%	1%	0.10%	1%
Maximum percentage of total revenue derived from sale of single-use (disposable) products	97%	98.10%	98%	96.80%

Revenue - Schedule of Contract

Revenue - Schedule of Contract Balance (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Accounts receivable,net	$ 6,791	$ 7,292
Contract liability—current	$ 362	$ 206

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Cash equivalents:
Money market funds	$ 13,042	$ 38,522
Total financial assets	13,042	38,522
Liability:
Contingent consideration liability	5,000	14,094
Total financial liabilities	5,000	14,094
Level 1
Cash equivalents:
Money market funds	13,042	38,522
Total financial assets	13,042	38,522
Level 3
Liability:
Contingent consideration liability	5,000	14,094
Total financial liabilities	$ 5,000	$ 14,094

Fair Value - Summary of Redeema

Fair Value - Summary of Redeemable Convertible Preferred Stock Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Redeemable Convertible Preferred Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value				$ 574	$ 624	$ 42
Change in fair value				3	(50)	582
Ending fair value				577	574	624
Derivative Liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value				46,147	44,128	38,007
Change in fair value				(23,383)	2,019	6,121
Ending fair value				22,764	46,147	44,128
Contingent Consideration Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value	$ 5,000	$ 8,943	$ 14,094	24,584	23,463	23,667
Change in fair value		(3,943)	(151)	(137)	1,121	(204)
Payment	0		(5,000)
Ending fair value	$ 5,000	$ 5,000	$ 8,943	$ 24,447	$ 24,584	$ 23,463

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Cash	$ 2,070	$ 2,086
Cash equivalents:
Money market funds	13,042	38,522
Total cash and cash equivalents	$ 15,112	$ 40,608

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Finished goods	$ 8,079	$ 9,495
Component materials	8,924	6,187
Total inventory	$ 17,003	$ 15,682

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Prepaid expenses	$ 1,735	$ 1,264
Prepaid insurance	411	2,726
Other current assets	119	149
Total prepaid expenses and other current assets	$ 2,265	$ 4,139

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 15,202	$ 13,911
Less: accumulated depreciation and amortization	(10,171)	(9,317)
Property and equipment, net	5,031	4,594
Computer and Software
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 407	730
Property and equipment, useful life	2 years
Machinery and Equipment
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 658	997
Property and equipment, useful life	3 years
Furniture and Fixtures
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 48	48
Property and equipment, useful life	7 years
Tools and Dies
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 903	941
Property and equipment, useful life	2 years
Construction in Progress
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 317	428
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 12,714	10,612
Property and equipment, useful life	3 years
Leasehold Improvements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 155	$ 155
Property and equipment, useful life, description	Lesser of useful life or lease term

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 0.6	$ 0.6	$ 1.9	$ 1.8
Amortization expense on intangible assets	2	2	6.1	6.1
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 0.6	$ 0.6	$ 1.7	$ 1.6

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Intangible Asset, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Line Items]
Gross Carrying Value	$ 48,315	$ 48,264
Accumulated Amortization	(19,431)	(13,294)
Net Carrying Value	28,884	34,970
Trademarks
Balance Sheet Components [Line Items]
Gross Carrying Value	3,969	3,969
Accumulated Amortization	(1,450)	(992)
Net Carrying Value	2,519	2,977
Developed Technology
Balance Sheet Components [Line Items]
Gross Carrying Value	30,819	30,819
Accumulated Amortization	(7,320)	(5,008)
Net Carrying Value	23,499	25,811
Customer Relationships
Balance Sheet Components [Line Items]
Gross Carrying Value	13,466	13,466
Accumulated Amortization	(10,661)	(7,294)
Net Carrying Value	2,805	6,172
Other intangible assets
Balance Sheet Components [Line Items]
Gross Carrying Value	61	10
Net Carrying Value	$ 61	$ 10

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Future Amortization Expense of Intangible Assets Related to Acquisition of Assets (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Balance Sheet Components [Abstract]
2022 (remaining three months)	$ 2,045
2023	5,376
2024	3,693
2025	3,693
Thereafter	14,016
Total	$ 28,823

Balance Sheet Components - Sc_6

Balance Sheet Components - Schedule of Accrued Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Accrued vacation	$ 1,468	$ 1,469
Accrued bonuses	1,805	1,307
Accrued commissions	690	665
Other accrued personnel related expenses	261	77
Total accrued compensation	$ 4,224	$ 3,518

Balance Sheet Components - Sc_7

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Accrual for litigation	$ 7,420	$ 7,203
Accrued professional fees	648	974
Accrued sales and use taxes	319	657
Deferred rent		277
Accrual for inventory in transit	253	119
Contract liability	362	206
Accrued interest expense	261	189
Others	1,121	1,037
Total accrued liabilities	$ 10,384	$ 10,662

Debt - CIBC Term loan - Additio

Debt - CIBC Term loan - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 08, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Convertible Notes
Debt Instrument [Line Items]
Interest expense on debt			$ 1,900		$ 5,900
Amortization of debt discount			600		1,700
CIBC Agreement
Debt Instrument [Line Items]
Payments of loan costs	$ 1,000
Interest Expense related to debt discount , debt issuance costs and exit fees		$ 100		$ 200
Interest expense on debt		900		2,200
CIBC Term Loan
Debt Instrument [Line Items]
Debt financing	$ 40,000	$ 40,000		$ 40,000		$ 40,000
Debt instrument effective interest rate		10%		10%
Ares Term Loan
Debt Instrument [Line Items]
Interest Expense related to debt discount , debt issuance costs and exit fees			900		1,900
Interest expense on debt			$ 1,900		$ 5,900

Debt - CIBC Term Loan - Schedul

Debt - CIBC Term Loan - Schedule of Debt (Details) - CIBC Term Loan - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Oct. 08, 2021
Debt Instrument [Line Items]
Term loan principal	$ 40,000	$ 40,000	$ 40,000
Less: Debt discount and debt issuance cost	(729)	(915)
Accrued interest	261	189
Term loan	$ 39,532	$ 39,274

Debt - Schedule of Contractual

Debt - Schedule of Contractual Maturities of Financing Obligations (Details) - CIBC Term Loan - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
2022 (remaining three months)	$ 856
2023	5,654
2024	15,765
2025	14,627
2026	12,405
Total	49,307
Less: unamortized debt discounts and issuance costs	(729)	$ (915)
Less: interest	(9,046)
Term loan	$ 39,532	$ 39,274

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)

1 Months Ended

3 Months Ended

8 Months Ended

9 Months Ended

14 Months Ended

25 Months Ended

Jul. 29, 2022 USD ($)

Nov. 12, 2020 USD ($)

Nov. 11, 2020 USD ($)

Apr. 22, 2020 USD ($)

Jul. 27, 2018 USD ($)

Jul. 31, 2019 USD ($)

Nov. 30, 2015 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Nov. 19, 2018 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Jun. 03, 2019 USD ($)

Aug. 28, 2020 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2017 USD ($)

Loss Contingencies [Line Items]

Rent expense recognized

$ 200,000

$ 200,000

$ 500,000

$ 600,000

Operating lease right-of-use asset

429,000

429,000

Operating lease liabilities

$ 565,000

$ 565,000

ASC 842

Loss Contingencies [Line Items]

Change in Accounting Principle, Accounting Standards Update, Adopted [true false]

true

true

Change in Accounting Principle, Accounting Standards Update, Adoption Date

Jan. 01, 2022

Jan. 01, 2022

California

Loss Contingencies [Line Items]

Lease commencement date

Jun. 01, 2023

Lease expiration date

May 31, 2028

Base rent payments

$ 88,341

Incremental annual rental payment percentage

3%

Letters of credit

$ 300,000

California | Restricted Cash

Loss Contingencies [Line Items]

Letters of credit

$ 300,000

$ 300,000

Office Leases | Santa Clara

Loss Contingencies [Line Items]

Letters of credit

$ 500,000

$ 500,000

$ 500,000

Hologic, Inc. and Cytyc Surgical Products, LLC

Loss Contingencies [Line Items]

Loss contingency damages sought value

$ 7,100,000

$ 16,000,000

Loss contingency damages awarded value

$ 4,800,000

$ 4,787,668

Supplement loss contingency damages and interest awarded

$ 7,100,000

$ 1,629,304

Prejudgment interest amount

$ 79,073

$ 270,533

Post-judgment interest rate

0.0228

0.0244

Loss contingency accrual for potential legal losses

$ 4,800,000

Hologic, Inc. and Cytyc Surgical Products, LLC | Surety Bond

Loss Contingencies [Line Items]

Loss contingency, increase in bond amount

$ 7,420,507

$ 7,203,414

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Lease Costs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Lease Cost
Operating lease cost	$ 490
Variable lease cost	186
Total lease cost	676
Other Information
Operating cash flows used for lease liabilities	631
Right of use asset acquired under operating lease on the adoption of ASC 842	$ 429
Weighted average remaining lease term (in years)	8 months 12 days
Weighted average incremental borrowing rate	4%

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022 (remaining three months)	$ 215
2023	358
Total undiscounted lease payments	573
Less: imputed interest	8
Total operating lease liability	565
Less: current portion	$ 565

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 846
2023	358
Total minimum lease payments	$ 1,204

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax benefit (expense)	$ 0	$ 0	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 01, 2022	Oct. 20, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized			100,000,000		100,000,000		100,000,000	100,000,000
Common stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001
Aggregate intrinsic value of stock options exercised					$ 0	$ 0
Fair value of options vested					$ 2,900,000	$ 5,100,000
Weighted average grant date fair value					$ 2.11	$ 7.07
Unrecognized stock-based compensation expense			$ 5,900,000		$ 5,900,000
Unrecognized stock-based compensation expense, weighted-average recognition period					2 years 2 months 12 days
Repurchase of common stock					0	0
Shares subject to repurchase					227,507		377,709
Aggregate exercise prices of early exercised shares					$ 100,000		$ 200,000
Preferred stock, shares authorized			5,000,000		5,000,000		5,000,000	5,000,000
Preferred stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common stock available for future grants			472,104		472,104		1,934,095
Risk-free interest rate			2.80%
Dividend rate			0%	0%	0%	0%
Expected term			6 years		6 years
Volatility			72.20%
Compensation expense			$ 1,977,000	$ 1,075,000	$ 5,176,000	$ 5,684,000
ESPP
Subsidiary or Equity Method Investee [Line Items]
Common stock available for future grants		401,164
Number of predicted shares		468,959
Maximum percentage of eligible compensation		15%
Purchase of common stock grant date share value		$ 25,000,000
Purchase price of common stock, percentage		85%
Compensation expense			100,000		200,000
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			3,500,000		$ 3,500,000
Unrecognized stock-based compensation expense, weighted-average recognition period					2 years 9 months 18 days
Number of shares, Granted					1,485,629
Compensation expense			852,000		$ 1,982,000
Tranche One | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense, weighted-average recognition period					1 month 6 days
Risk-free interest rate	2.15%
Dividend rate	0%
Expected term	6 months
Volatility	74.52%
Tranche Two | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			200,000		$ 200,000
Unrecognized stock-based compensation expense, weighted-average recognition period					1 year
Risk-free interest rate	2.15%
Dividend rate	0%
Expected term	1 year
Volatility	65.14%
Maximum
Subsidiary or Equity Method Investee [Line Items]
Expected term				6 years		6 years
Maximum | ESPP
Subsidiary or Equity Method Investee [Line Items]
Purchase shares of common stock		10,000
Maximum | Tranche One | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			$ 100,000		$ 100,000
Minimum
Subsidiary or Equity Method Investee [Line Items]
Expected term				5 years		5 years

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of common stock warrants (Details) - $ / shares	Jul. 19, 2019	May 09, 2017	Sep. 30, 2022
Equity [Abstract]
Issuance Date	Jul. 19, 2019	May 09, 2017
Number of Shares of Common Stock Issuable	43,878	33,964	77,842
Exercise Price	$ 11.31	$ 11.31
Classification	Equity	Equity
Expiration Date	Jul. 18, 2029	May 08, 2027

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Shares Reserved for Future Issuance (Details) - shares	Sep. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Warrants to purchase common stock	77,842	77,842
Common stock options issued and outstanding	2,183,311	2,175,685
Common stock available for future grants	472,104	1,934,095
Restricted Stock Units Issued And Outstanding	1,703,213	394,750
ESPP
Class Of Stock [Line Items]
Convertible notes	401,164	401,164

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares Underlying Outstanding Options, Beginning balance | shares	2,175,685
Number of Shares Underlying Outstanding Options, Granted | shares	189,800
Number of Shares Underlying Outstanding Options, Exercised | shares	(56,964)
Number of Shares Underlying Outstanding Options, Forfeited or Cancelled | shares	(125,210)
Number of Shares Underlying Outstanding Options, Ending balance | shares	2,183,311	2,175,685
Number of Shares Underlying Outstanding Options, Shares Exercisable | shares	1,577,934
Number of Shares Underlying Outstanding Options, Vested and Expected to Vest | shares	2,183,311
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 9.27
Weighted Average Exercise Price, Options granted | $ / shares	3.27
Weighted Average Exercise Price, Options exercised | $ / shares	0.61
Weighted Average Exercise Price, Options forfeited or cancelled | $ / shares	8.71
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	9	$ 9.27
Weighted Average Exercise Price, Shares exercisable | $ / shares	9.66
Weighted Average Exercise Price, vested and expected to vest | $ / shares	$ 9
Weighted Average Remaining Contractual Term (in years), Outstanding	8 years 1 month 6 days	8 years 8 months 12 days
Weighted Average Remaining Contractual Term (in years), Shares exercisable	7 years 9 months 18 days
Weighted Average Remaining Contractual Term (in years), Vested and Expected to Vest	8 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding | $	$ 99	$ 2,856
Aggregate Intrinsic Value, Shares exercisable | $	81
Aggregate Intrinsic Value, Vested and expected to vest | $	$ 99

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Outstanding Restricted Stock, Unvested, Beginning Balance | shares	394,750
Number of Shares Underlying Outstanding Restricted Stock, Granted | shares	1,485,629
Number of Shares Underlying Outstanding Restricted Stock, Exercised/released | shares	88,938
Number of Shares Underlying Outstanding Restricted Stock, Forfeited or cancelled | shares	(88,228)
Number of Shares Underlying Outstanding Restricted Stock, Unvested, Ending Balance | shares	1,703,213
Weighted Average Grant Date Fair Value, Unvested, Beginning Balance | $ / shares	$ 5.17
Weighted Average Grant Date Fair Value, Unvested, Granted | $ / shares	2.57
Weighted Average Grant Date Fair Value, Unvested, Exercised/released | $ / shares	2.85
Weighted Average Grant Date Fair Value, Unvested, Forfeited or Cancelled | $ / shares	3.09
Weighted Average Grant Date Fair Value, Unvested, Ending Balance | $ / shares	$ 3.13

Stockholders' Equity -Summary o

Stockholders' Equity -Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Class Of Stock [Line Items]
Stock-based compensation expense	$ 1,977	$ 1,075	$ 5,176	$ 5,684
Cost of Goods Sold
Class Of Stock [Line Items]
Stock-based compensation expense	97	66	240	236
Sales and Marketing
Class Of Stock [Line Items]
Stock-based compensation expense	729	406	1,918	1,701
Research and Development
Class Of Stock [Line Items]
Stock-based compensation expense	4	8	33	127
General and Administrative
Class Of Stock [Line Items]
Stock-based compensation expense	1,147	595	2,985	3,620
ESPP
Class Of Stock [Line Items]
Stock-based compensation expense	171		225
Stock Options
Class Of Stock [Line Items]
Stock-based compensation expense	954	$ 1,075	2,969	$ 5,684
Restricted Stock Units
Class Of Stock [Line Items]
Stock-based compensation expense	$ 852		$ 1,982

Stockholders' Equity -Schedule

Stockholders' Equity -Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0%	0%	0%	0%
Volatility	72.20%
Expected volatility minimum		73.30%	70.80%	72.90%
Expected volatility maximum		75%	72.20%	75.90%
Risk-free interest rate	2.80%
Risk-free interest rate minimum		0.90%	1.90%	0.60%
Risk-free interest rate maximum		1.10%	3%	1.10%
Expected term	6 years		6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		5 years		5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years		6 years

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator
Net Loss Attributable to Common Stockholders	$ (11,329)	$ (5,613)	$ (10,925)	$ (3,225)	$ (14,099)	$ (14,948)	$ (27,867)	$ (32,272)
Denominator:
Weighted-average common stock outstanding	28,611,045			2,798,146			28,553,949	2,145,733
Net loss per share attributable to common stockholders, basic	$ (0.40)			$ (1.15)			$ (0.98)	$ (15.04)
Net loss per share attributable to common stockholders, diluted	$ (0.40)			$ (1.15)			$ (0.98)	$ (15.04)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Redeemable Convertible Preferred Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		77,842
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	77,842
Unvested Early Exercised Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	227,507	410,788
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,183,311	2,170,894
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,703,213
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		12,397,838

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ in Millions	Nov. 10, 2022 USD ($)
Subsequent Event | Hologic
Subsequent Event [Line Items]
Legal settlement obligation	$ 7.4